ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inh
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
| Condition(s) | Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis. |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years * Able to understand the written informed and able to give informed consent * Locally advanced or metastatic NSCLC with oncogenic driver mutation * Treatment with TKI according to standard of care Exclusion Criteria: * Unable to draw blood for study purposes |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Erasmus Medical Center |
| Locations | Rotterdam, Netherlands |
| Start date | 2017-02-02 |
| NCT ID | NCT05221372 |
| Official listing | https://clinicaltrials.gov/study/NCT05221372 |